| Oral, small-molecule inhibitor of JAK1 being developed by Pfizer for the treatment of moderate-to-severe AD. |
| Received its first approval on 9 September 2021 in the UK. |
| Approved for the treatment of moderate-to-severe AD in adults and adolescents 12 years and older who are candidates for systemic therapy. |
Official websites use .gov
A
.gov website belongs to an official
government organization in the United States.
Secure .gov websites use HTTPS
A lock (
) or https:// means you've safely
connected to the .gov website. Share sensitive
information only on official, secure websites.